An antimicrobial peptide based on MCR-1 protein and its application

By designing 24AA-2M and 19AA-2M-tag antimicrobial peptides based on the MCR-1 protein, which bind to and disrupt bacterial cell membranes, the problem of antibiotic resistance has been solved, providing a highly effective and low-toxicity antimicrobial treatment option.

CN116375824BActive Publication Date: 2026-11-17SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310228588.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-09
Publication Date
2026-11-17
Estimated Expiration
2043-03-09

AI Technical Summary

Technical Problem

The serious problem of antibiotic resistance limits treatment options and urgently requires the development of new antimicrobial drugs. However, natural antimicrobial peptides have drawbacks such as low content, high production costs, and easy biodegradability.

Method used

Antimicrobial peptides based on MCR-1 protein, namely 24AA-2M and 19AA-2M-tag, were designed and synthesized. Their stability was improved by adding a 5-tryptophan tag to the C-terminus. They bind to and disrupt bacterial cell membranes, exhibit broad-spectrum antimicrobial activity, and synergize with colistin.

Benefits of technology

It achieves highly efficient killing of a variety of bacteria, reduces immunogenicity and cytotoxicity, and provides a new treatment option for drug-resistant bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116375824B_ABST
    Figure CN116375824B_ABST
Patent Text Reader

Abstract

This invention discloses an antimicrobial peptide based on MCR-1 protein and its applications. The sequence of the antimicrobial peptide is shown in SEQ ID NO.1 or SEQ ID NO.2. The antimicrobial peptide of this invention has a short synthetic length, which not only greatly reduces production costs but also effectively reduces the immunogenicity and cytotoxicity of the antimicrobial peptide. Experiments have also confirmed that both small molecule peptides can bind to and disrupt bacterial cell membranes, exhibiting broad-spectrum antimicrobial activity both in vivo and in vitro. Moreover, the short antimicrobial peptide of this invention can synergistically enhance the antibacterial activity of colistin, allowing for combined drug therapy and providing a new treatment option for colistin-resistant bacterial infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to an antimicrobial peptide based on MCR-1 protein and its application. Background Technology

[0002] Over the past two decades, bacterial resistance caused by the overuse of antibiotics has become a serious public health and safety issue of global concern. The emergence and increasing severity of bacterial resistance are causing existing effective antibacterial drugs to become ineffective, gradually limiting the choice of treatment options. With the widespread use of colistin, reports of its resistance are also increasing. In late 2015, Chinese scholars reported for the first time the isolation of the plasmid-mediated colistin resistance gene MCR-1 (mobile colistin resistance) from *Escherichia coli* isolated from humans and animals. The MCR-1 protein can reduce the affinity of colistin for lipid A on the extracellular membrane lipopolysaccharide through covalent modification, thereby making bacteria insensitive to colistin. This resistance can also be transmitted through plasmids, leading to a rapid increase in resistance rates. Faced with such a serious situation of bacterial resistance, there is an urgent need to develop new drugs and design more effective treatment methods to treat infections caused by drug-resistant bacteria.

[0003] Antimicrobial peptides (AMPs) are short peptides that bind tightly to lipopolysaccharide (LPS) on bacterial membrane surfaces. Due to their unique membrane-disrupting antimicrobial mechanism, they are less prone to developing drug resistance, making them a promising strategy for overcoming the problem of acute antibiotic resistance and possessing broad application prospects. However, natural antimicrobial peptides often suffer from drawbacks such as low content, high production costs, and susceptibility to biodegradation, necessitating modification and optimization. Currently, commonly used methods to improve the efficiency of antimicrobial peptides mainly include protein engineering technology, chemical modification, computer molecular simulation, and machine deep learning technology. Summary of the Invention

[0004] The purpose of this invention is to provide an antimicrobial peptide based on MCR-1 protein and its application.

[0005] The technical solution adopted in this invention is: In a first aspect, the present invention provides a polypeptide having the sequence shown in SEQ ID NO.1 or SEQ ID NO.2.

[0006] In a second aspect, the present invention provides a nucleic acid molecule encoding the polypeptide described in the first aspect of the present invention.

[0007] In some embodiments of the present invention, the nucleic acid molecule may be the nucleic acid molecule shown in 1), 2), 3), or 4) below: 1) The DNA molecule encoding the polypeptide; 2) The cDNA molecule encoding the polypeptide; 3) Having 75% or more identity with the nucleotide sequence defined in 1) or 2) and encoding the polypeptide in a cDNA molecule or genomic DNA molecule; 4) Hybridizes under stringent conditions to the nucleotide sequence defined in 1) or 2) and to a cDNA molecule or genomic DNA molecule encoding the polypeptide.

[0008] A third aspect of the present invention provides a carrier comprising the nucleic acid molecule described in the second aspect of the present invention.

[0009] In some embodiments of the present invention, the vector includes plasmids, granules, bacteriophages, or viral vectors.

[0010] In a fourth aspect, the present invention provides a cell comprising the carrier described in the third aspect of the present invention.

[0011] In some embodiments of the present invention, the cells include yeast, bacteria, algae, or fungi.

[0012] A fifth aspect of the invention provides the use of the polypeptide described in the first aspect of the invention, the nucleic acid molecule described in the second aspect of the invention, the carrier described in the third aspect of the invention, or the cell described in the fourth aspect of the invention in the following (I) or (II): (I) Preparation of microbial inhibitors; (II) Preparation of additives.

[0013] In some embodiments of the present invention, the microorganism is bacteria.

[0014] In some embodiments of the present invention, the bacteria include at least one of Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus.

[0015] In some embodiments of the present invention, the additive is a cosmetic additive.

[0016] In a sixth aspect, the present invention provides a method for preparing the polypeptide described in the first aspect of the present invention, wherein the preparation method is the Fmoc solid-phase synthesis method.

[0017] A seventh aspect of the present invention provides a pharmaceutical or cosmetic additive comprising the polypeptide described in the first aspect of the present invention.

[0018] In some embodiments of the present invention, the drug also includes antibiotics.

[0019] In some embodiments of the present invention, the antibiotic includes colistin.

[0020] In some embodiments of the present invention, the concentration of the antibiotic is at least 46.25 μM.

[0021] In some preferred embodiments of the present invention, the concentration of the antibiotic is 46.25–185 μM.

[0022] In some embodiments of the present invention, pharmaceutical or cosmetic additives containing polypeptides can be prepared into single-dosage or multi-dosage formulations using pharmaceutically acceptable carriers and / or excipients, according to methods commonly employed by those skilled in the art. The formulation may be an oral preparation, such as a powder, granules, tablet, capsule, suspension, emulsion, syrup, aerosol, etc. The formulation may be formulated for external application, such as an ointment, cream, etc., or any other pharmaceutical preparation, such as a suppository, sterile solution for injection, etc. In some embodiments, the pharmaceutical or cosmetic additive may further contain a dispersant or stabilizer.

[0023] An eighth aspect of the present invention provides a method for inhibiting microbial growth, comprising the step of applying the pharmaceutical or cosmetic additive described in the seventh aspect of the present invention.

[0024] In some embodiments of the present invention, the microorganism is bacteria.

[0025] In some embodiments of the present invention, the bacteria include at least one of Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus.

[0026] The beneficial effects of this invention are: This invention designs and synthesizes a 24-amino acid antimicrobial short peptide, named 24AA-2M, based on the lipid A-binding pocket domain of an MCR-1 mutant. Its amino acid sequence is: KALRSYVNSIMPIYSVGKLASIEY (SEQ ID NO. 1). To improve the stability of the short peptide, a 5-tryptophan (5W) tag is added to the C-terminus of the peptide, resulting in the design and synthesis of a derivative of 24AA-2M, named 19AA-2M-tag, with the amino acid sequence: KALRSYVNSIMPIYSVGKLWWWWW (SEQ ID NO. 2). The short synthetic lengths of 24AA-2M and 19AA-2M-tag not only significantly reduce production costs but also effectively decrease the immunogenicity and cytotoxicity of the antimicrobial peptide. Experiments have also confirmed that both small molecule peptides can bind to and disrupt bacterial cell membranes, exhibiting broad-spectrum antimicrobial activity both in vivo and in vitro. Furthermore, the antimicrobial short peptide of the present invention can synergistically work with colistin to significantly enhance the antibacterial activity of colistin, and can be used in combination, providing a new treatment option for the treatment of colistin-resistant bacterial infections. Attached Figure Description

[0027] Figure 1The killing time of antimicrobial peptides 24AA-2M and 19AA-2M-tag against Escherichia coli was determined.

[0028] Figure 2 The effects of antimicrobial peptides 24AA-2M and 19AA-2M-tag on bacterial cell membrane permeability were investigated. Figure 2 A represents the effect of antimicrobial peptides 24AA-2M and 19AA-2M-tag on Escherichia coli membranes; Figure 2 B represents the PI staining result; Figure 2 C represents the percentage of PI-positive bacteria.

[0029] Figure 3 IC50 determination of antimicrobial peptide 19AA-2M-tag against various Gram-positive and Gram-negative bacterial standard strains.

[0030] Figure 4 This study demonstrates the synergistic inhibitory effect of antimicrobial peptide 19AA-2M-tag and colistin on the growth of Escherichia coli. Figure 4 A represents the results of the chessboard experiment; Figure 4 B represents the optimized concentration for the synergistic use of antimicrobial peptide 19AA-2M-tag and colistin.

[0031] Figure 5 The toxic effects of antimicrobial peptides 24AA-2M and 19AA-2M-tag on erythrocytes.

[0032] Figure 6 To observe the in vivo efficacy of antimicrobial peptide 19AA-2M-tag in a mouse peritonitis infection model. Detailed Implementation

[0033] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

[0034] This invention employs various antibacterial validation tests, including bactericidal time determination and membrane permeability analysis, to observe the in vitro bactericidal effects of these two antimicrobial peptides and verify their bactericidal mechanism. Since the linker domain of the MCR-1 protein is an important region for binding lipid A on the outer membrane of Gram-negative bacteria, it is speculated that the main mechanism of action of this synthetic antimicrobial peptide is to bind and disrupt the bacterial outer membrane. To verify its antimicrobial activity and mechanism, the Escherichia coli ATCC25922 standard strain was first selected, and the antimicrobial activity of these two antimicrobial peptides against Gram-negative enterobacteria was confirmed through bactericidal time determination and membrane permeability analysis.

[0035] Example 1: Preparation of antimicrobial peptides In their research on MCR-1, the applicant discovered an MCR-1 mutant with a mutation at a key site in the linker region of the MCR-1 protein. This mutated region is crucial for the binding of lipid A on lipopolysaccharide (LPS). Based on this, a potential therapeutic approach derived from the drug resistance gene itself was developed to kill drug-resistant bacteria. Using the lipid A-binding pocket sequence of this MCR-1 mutant as a template, the applicant designed and synthesized a 24-amino acid antimicrobial short peptide, named 24AA-2M, with the amino acid sequence: KALRSYVNSIMPIYSVGKLASIEY (SEQ ID NO. 1). To improve the stability of the short peptide, a 5-tryptophan (5W) tag was added to the C-terminus of the peptide, resulting in the design and synthesis of a derivative of 24AA-2M, named 19AA-2M-tag, with the amino acid sequence: KALRSYVNSIMPIYSVGKLWWWWW (SEQ ID NO. 2).

[0036] 24AA-WT (KPLRSYVNPIMPIYSVGKLASIEY (SEQ ID NO.3)), 24AA-2M, and 19AA-2M-tag were synthesized using chemical synthesis methods. The target peptides were synthesized sequentially from the C-terminus (carboxyl terminus) to the N-terminus (amino terminus). During the synthesis, the alpha amino group was protected using an Fmoc group. After synthesis, the side chain protecting groups and resin were cleaved. The specific synthesis process is as follows: Peptide synthesis follows the solid-phase synthesis principle. In a sealed, explosion-proof glass reactor, amino acids are added, reacted, and synthesized in a known sequence (generally from the C-terminus to the N-terminus to the amino-terminus) to ultimately obtain a peptide carrier. To prevent side reactions, the side chains of the amino acids participating in the reaction are protected. The carboxyl terminus is free and must be activated before the reaction.

[0037] The solid-phase synthesis method mainly uses Fmoc. First, the resin is activated. A certain amount of resin is placed in a solid-phase reactor, and 5.0 mL of anhydrous DMF (N,N-dimethylformamide) is added to soak and swell for 2 hours. The solvent DMF is then removed under reduced pressure. Next, amino acids are coupled. The activated Fmoc-AA-OH:4.0 eq. Fmoc protected amino acid, 3.6 eq. HOBt, and 8.0 eq. DIPEA are dissolved in 4.0 mL of DMF. The first amino acid is coupled to the resin by dissolving 4 eq. Fmoc protected amino acids 3.6 eq. HBTU and 0.1 eq. DMAP in 4.0 mL of DMF, adding 8 eq. DIPEA, and shaking at room temperature for 10 hours. The solvent is then removed under reduced pressure, and the resin is washed with DMF (4.0 mL × 5). Immediately afterwards, 6.0 mL of a solution of acetic anhydride:pyridine:DMF = 2:1:3 is added, and the mixture is shaken for 30 minutes to block unreacted functional groups on the resin. The resin was washed sequentially with DMF (4.0 mL × 3), DCM (dichloromethane, 4.0 mL × 3), and DMF (4.0 mL × 3), followed by deprotection with 20% pyridinium / DMF (4.0 mL × 3) for 10 minutes and 20 minutes respectively. Then, the peptide coupling reaction was initiated. Except for Fmoc-Ser / Thr(Ac3-β-O-G1cNAc)-OH, which was added at twice the normal volume, the other amino acid activation methods were as follows: 4 eq. of Fmoc-protected amino acid, 3.6 eq. mmol HBTU, 4 eq. HOBt, and 8 eq. DIPEA were dissolved in 4.0 mL of DMF. The reaction solution was added to the solid-phase reactor and shaken at room temperature for 2 hours. After coupling, Kaiser's reagent was used for detection. A positive reaction indicated incomplete coupling, and the coupling steps were repeated. Next, the peptide was excised and precipitated. The resin was washed several times with DCM and then dried under vacuum. 5.0 mL of a solution of trifluoroacetic acid / triisopropylsilane / water (TFA / TIS / H2O) = 95 / 2.5 / 2.5 (v / v) was slowly added to a peptide solid-phase reactor containing resin, and the reaction was allowed to proceed for 3 hours. After filtration and removal of most of the solvent by nitrogen purging, 20.0 mL of anhydrous diethyl ether was added to the residue, resulting in a white flocculent precipitate. The precipitate was centrifuged at 4000 RPM and 5°C for 5 minutes, the diethyl ether solvent was discarded, and 20.0 mL of anhydrous diethyl ether was added to the precipitate. The mixture was shaken and centrifuged for 5 minutes under the same conditions, and this process was repeated once more to remove most of the impurities. The precipitate was then vacuum-dried for 24 hours. The solid residue was dissolved in deionized water and freeze-dried to obtain a white flocculent solid, which was stored at -20°C. Finally, the synthesized peptide was separated and purified. The freeze-dried crude peptide was dissolved in a 20% acetonitrile / water solution and separated by high-performance liquid chromatography (HPLC). HPLC was performed on a Waters-600E multichannel system using a DEVELOSIL ODS-UG-5 C18 semi-preparative column.A 10.0 × 250 mm column and a Waters-2487 UV detector (λ = 215 and 254 nm), or a Varian (Pro Star 215) CC 125 / 4 nucleodur C18 gravity column were used for preparation. Gradient elution was performed with acetonitrile and aqueous solution containing 0.6% TFA. The major peak product was collected and identified by electrospray ionization mass spectrometry or MALDI-TOF mass spectrometry. Acetonitrile was removed from the HPLC sample peak by rotary evaporation under reduced pressure. The target product peptide was obtained by freeze drying and stored at -20 °C.

[0038] Example 2: Determination of lethal time Adjust the density of the overnight culture of Escherichia coli ATCC25922 with physiological saline to the absorbance (OD) value. 600 =0.5, and further diluted 1:10. The diluted cultures were treated with 24AA-WT, 24AA-2M, and 19AA-2M-tag synthetic peptides at concentration gradients of 370, 185, and 92.5 μM, respectively. Untreated dimethyl sulfoxide (DMSO) was used as a blank control, and 5W was used as a modified peptide control. For each treatment sample, 100 µL of culture was taken at 0, 3, 6, and 24 hours after the addition of the target peptide and diluted with physiological saline in six serial dilutions, ranging from 10 μM to 10 μW. -1 Up to 10 -6 Then, 3 μL of each dilution was applied to LB agar plates, with each treatment repeated three times. After incubation at 37°C for 18 hours, the number of colonies grown on the LB plates was counted, and colony forming units (CFU) were calculated to evaluate the antibacterial effect.

[0039] The results are as follows Figure 1 As shown, the linker peptide 24AA-WT of wild-type MCR-1, serving as a control, exhibited no antibacterial activity. In contrast, the antimicrobial peptide 24AA-2M was active against Escherichia coli ATCC25922, with its antibacterial effect lasting for 6 hours and increasing with increasing concentration, but weakening after 6 hours. The antimicrobial peptide 19AA-2M-tag showed the same antibacterial effect as 24AA-2M, but with greater stability and a longer duration of action, maintaining its antibacterial effect even after 24 hours. This indicates that the modified 19AA-2M-tag can effectively retain antibacterial activity and has better stability than 24AA-2M, showing greater application potential.

[0040] Example 3 Membrane permeability analysis Cell membrane integrity was analyzed using scanning electron microscopy and propidium iodide (PI) staining. Propidium iodide (PI) is an analogue of ethidium bromide that emits red fluorescence after intercalation into double-stranded DNA. PI cannot pass through the membranes of living cells, but it can penetrate damaged cell membranes to enter cells and bind to DNA and RNA within the damaged cells, thus staining nucleic acids. Therefore, PI staining can be used to analyze whether cell membrane permeability is increased.

[0041] The PI staining procedure is as follows: A single colony of fresh *Escherichia coli* ATCC25922 is picked and inoculated into fresh LB broth, and incubated overnight at 37 °C. The OD of the overnight culture is then adjusted with physiological saline. 600 The concentration was adjusted to between 0.5 and 0.6, and the cultures were passaged into 1 mL of LB broth containing different concentrations of 19AA-2M or 24AA-2M-tag (concentration gradients of 23.12, 46.25, 92.5, and 185 μM). After incubation for 2 hours, the cultures were collected by centrifugation at 4000 rpm for 3 min, washed twice with physiological saline, and resuspended in 95 µL of buffer A (PI staining kit, Sangon Biotech). Then, 5 µL of PI dye was added to each resuspended culture, and the cultures were incubated in the dark for 15 min. The percentage of PI-positive cultures was determined by flow cytometry (Gallios 10, Beckman Coulter). Unstained cultures were used as gated controls. Data were analyzed using FlowJo v.10 software and plotted using Prism 9 software.

[0042] The results are as follows Figure 2 As shown, the addition of the antimicrobial peptide 24AA-2M to Escherichia coli caused bacterial shrinkage, and the Escherichia coli membrane treated with 19AA-2M-tag showed wrinkling, cracks, and leakage of cell contents. Figure 2 A). PI staining showed that cells treated with 24AA-2M and 19AA-2M-tags both increased the proportion of PI-positive bacteria in a dose-dependent manner. Figure 2 B and Figure 2 C) revealed that it has a membrane-attacking effect that enhances the permeability of both the bacterial inner and outer membranes, and that 19AA-2M-tag exhibits higher membrane-attacking activity and a lower effective concentration against Escherichia coli. Figure 2 (C) indicates that both 24AA-2M and 19AA-2M-tag kill bacteria through cell membrane damage, with 19AA-2M-tag being more potent.

[0043] Next, in the efficacy assay of the antimicrobial peptide, 19AA-2M-tag, which has a stronger and more stable effect, was selected for further analysis. To determine its antimicrobial spectrum, the half-maximal inhibitory concentration (IC50) of the antimicrobial peptide 19AA-2M-tag against various Gram-positive and Gram-negative standard strains was determined. IC50 refers to the drug concentration required to reduce the number of surviving bacteria by half after administration. The tested bacterial strains included Escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC27853, Salmonella typhimurium SL1343, Klebsiella pneumoniae ATCC13883, Acinetobacter baumannii ATCC19606, and Staphylococcus aureus ATCC25913. The results are as follows: Figure 3 As shown, the IC50 of the tested Gram-negative bacterial strains 50 The IC50 value for Gram-positive Staphylococcus aureus ranged from 30.82 to 64.45 μM. 50 The value was slightly high, at 87.44 μM, indicating that the antimicrobial peptide 19AA-2M-tag has a broad-spectrum antimicrobial activity and is effective against both Gram-positive and Gram-negative bacteria.

[0044] Example 4: Chessboard Experiment To further understand whether antimicrobial peptides can be used with colistin to produce a synergistic antibacterial effect, the combined drug efficacy was further analyzed. A checkerboard analysis was used to determine the interaction between colistin (CT) and 19AA-2M-tag on the inhibitory activities of Escherichia coli standard strain ATCC25922 and clinically isolated carbapenem-resistant multidrug-resistant Escherichia coli strain CRE-SRY. This was compared with their individual effects to determine whether the combination produced a synergistic effect and whether it had a synergistic inhibitory effect on clinically multidrug-resistant Enterobacteriaceae. The specific experimental procedures are as follows: A checkerboard assay was established using 96-well plates. Columns 2 to 12 show serially diluted colistin (range 10 to 0.0098 μg / mL), and rows A to G show serially diluted 19AA-2M-tag (range 92.5 to 1.45 μM). Column 1 shows serially diluted 19AA-2M-tag alone (range 92.5 to 1.45 μM), and row H shows serially diluted colistin alone (range 10 to 0.0098 μg / mL). These two groups served as controls, and the minimum inhibitory concentration (MIC) of colistin or 19AA-2M-tag against Escherichia coli was determined. Escherichia coli ATCC25922 and CRE-SRY (a carbapenem-resistant Escherichia coli clinically isolated) were cultured to the logarithmic growth phase, diluted with LB broth, and the absorbance (OD) was adjusted to OD. 600=0.5. After diluting at a ratio of 1:10, 20 µL of the diluted culture was added to 180 µL of LB broth containing colistin and / or 19AA-2M-tag. The absorbance (OD) per well at 600 nm was measured using a nanophotometer (NP80, IMPLEN) after incubation at 37 °C for 0 h and 16 h. 600 The synergistic effect was further determined by calculating the fractional inhibition concentration index (FICI). The formula for calculating the fractional inhibition concentration index (FICI) is as follows:

[0045] Wherein MIC A combined and MIC B combined are the minimum inhibitory concentrations (MICs) for each drug used in combination, and MIC A alone and MIC B alone are the MICs for each drug used alone.

[0046] Experimental results are as follows Figure 4 As shown, Figure 4 In diagram A, orange represents bacterial growth, while blue represents growth inhibition. The antimicrobial peptide 19AA-2M-tag and colistin (CT) exhibit synergistic bactericidal activity against *Escherichia coli* ATCC25922 (FICI=0.312) and clinically collected carbapenem-resistant Enterobacteriaceae (CRE) isolates (FICI=0.156). The applicant further analyzed the optimized concentration of the antimicrobial peptide 19AA-2M-tag in synergistic use with colistin, from... Figure 4 The dose-response curve of B shows that the inhibitory effect of colistin on Escherichia coli ATCC25922 is significantly accelerated after the addition of the antimicrobial peptide 19AA-2M-tag compared to the absence of the antimicrobial peptide, reaching 100% inhibition more quickly. This demonstrates that adding an antimicrobial peptide at a concentration as low as 46.25 μM can significantly improve the antimicrobial activity of colistin, indicating a synergistic effect between the two. These results indicate that the antimicrobial peptide designed and synthesized in this invention has a synergistic effect with colistin and can be used in combination, providing a new treatment option for colistin-resistant bacterial infections.

[0047] To further investigate whether the antimicrobial peptide 19AA-2M-tag also exhibits antibacterial activity against other commonly used drug-resistant bacteria, the antimicrobial effects of 19AA-2M-tag against three standard strains of Escherichia coli and common, easily resistant pathogens were tested. The pathogens included standard strains of Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus, as well as clinically isolated drug-resistant strains, including amikacin-resistant Acinetobacter baumannii, carbapenem-resistant Enterobacteriaceae (Escherichia coli and Klebsiella pneumoniae), methicillin-resistant Staphylococcus aureus, and colistin-resistant Escherichia coli.

[0048] Table 1. Antimicrobial activity of antimicrobial peptide 19AA-2M-tag against standard strains and common clinically resistant pathogens.

[0049] The results are shown in Table 1. For both drug-resistant and non-drug-resistant standard strains, the minimum inhibitory concentration (MIC) of antimicrobial peptide 19AA-2M-tag against Gram-negative strains was in the range of 92.5-370 μM, showing good antimicrobial activity. All clinically isolated drug-resistant bacteria were sensitive to antimicrobial peptide 19AA-2M-tag. For Gram-positive Staphylococcus aureus standard strain and MASA multidrug-resistant strain, antimicrobial peptide 19AA-2M-tag also showed good antimicrobial activity, with an MIC value of 370 μM. This indicates that antimicrobial peptide 19AA-2M-tag, derived from the colistin resistance gene, can also show broad-spectrum antimicrobial activity against clinically drug-resistant strains.

[0050] Example 5 Mouse erythrocyte lysis test For new drugs, toxicity is a crucial indicator that needs to be determined, as it relates to whether the drug can be administered in vivo and its future application prospects. The synthetic peptides of this invention are relatively short, consisting of only 24 amino acid residues, and are expected to effectively reduce the cytotoxicity of antimicrobial peptides. To confirm whether they exhibit membrane toxicity to host cells while increasing bacterial outer membrane permeability, a mouse erythrocyte lysis assay was used to observe the in vitro toxic effects of antimicrobial peptides 24AA-2M and 19AA-2M-tag on erythrocyte membranes.

[0051] Cell membrane toxicity was determined using the lactate dehydrogenase (LDH) method. Each peptide was diluted with physiological saline to a final concentration gradient of 46.25, 92.5, 185, and 370 µM. Mouse peripheral blood erythrocytes were first added to 96-well plates (3000 erythrocytes / well), and then 100 µL of the different concentrations of peptide were repeatedly added to different wells of the plate, with a colistin-treated sample used as a control for comparison. After co-incubation of erythrocytes and peptides for 2 hours, the amount of LDH released from cells was quantitatively determined using an LDH cytotoxicity assay kit (Sigma). Each measurement was repeated three times, and the average value was calculated and plotted using Prism 9.

[0052] The results are as follows Figure 5 The results showed that both antimicrobial peptides 24AA-2M and 19AA-2M-tag had very low cytotoxicity to erythrocytes. Compared with 24AA-2M, 19AA-2M-tag had even lower cytotoxicity, almost close to zero, indicating that neither of these two small molecule antimicrobial peptides had a lytic effect on the cell membrane of erythrocytes and did not produce cytotoxic effects.

[0053] Example 6 Antibacterial test in a mouse infection model To verify the in vivo therapeutic effect of antimicrobial peptides, 19AA-2M-tag, which has lower toxicity, was selected and subjected to in vivo antimicrobial experiments in a mouse infection model to observe its in vivo antimicrobial effect.

[0054] Ten-week-old C57BL / 6 mice were infected with either the standard strain ATCC25922 or the clinically resistant strain CRE-SRY via intraperitoneal injection. Each mouse was injected with 1×10⁻⁶ Escherichia coli. 7 CFU bacteria. One hour after infection, mice were treated by intraperitoneal injection of 250 μg of 19AA-2M-tag, with mice receiving intraperitoneal injection of DMSO as controls. Each condition was repeated three times. Mice were sacrificed 24 hours after infection, and liver and spleen tissue homogenates were collected. Serially diluted tissue homogenates were spotted onto LB agar plates and incubated at 37°C for 16 hours. CFU counts were then performed to determine the bacterial load in the liver and spleen to evaluate the antibacterial effect.

[0055] The results are as follows Figure 6 As shown, the antimicrobial peptide 19AA-2M-tag demonstrated good in vivo efficacy against both Escherichia coli ATCC25922 and clinically isolated multidrug-resistant strains of CRE in a mouse model of peritonitis. Liver and spleen CFU counts showed that 19AA-2M-tag significantly reduced the bacterial load in the liver and spleen of mice. The therapeutic effects on standard strains and clinically resistant strains of Escherichia coli were similar, confirming that the antimicrobial peptide 19AA-2M-tag has good in vivo efficacy and also shows good therapeutic effect against drug-resistant strains.

[0056] In summary, both small-molecule antimicrobial peptides designed and synthesized in this invention can bind to and disrupt bacterial cell membranes to produce antimicrobial effects, exhibiting broad-spectrum, highly efficient, and low-toxicity antimicrobial activity. The modified 19AA-2M-tag exhibits stronger antimicrobial activity and better stability, demonstrating good therapeutic effects both in vivo and in vitro. In application, 19AA-2M-tag was found to have a synergistic effect with colistin, showing good efficacy against clinically resistant strains as well. Thus, based on the product of drug resistance genes, two novel antimicrobial peptides were designed and synthesized, establishing a novel design paradigm derived from the drug resistance gene itself to kill drug-resistant bacteria, and developing a novel drug against drug-resistant bacteria. This design concept and the antimicrobial peptide protein sequence have not been reported before.

[0057] The above detailed embodiments have provided a comprehensive description of the present invention. However, the present invention is not limited to the above embodiments. Within the scope of knowledge possessed by those skilled in the art, various changes can be made without departing from the spirit of the present invention. Furthermore, unless otherwise specified, the embodiments of the present invention and the features thereof can be combined with each other.

Claims

1. A polypeptide having the sequence shown in SEQ ID NO.1 or SEQ ID NO.

2.

2. A nucleic acid molecule encoding the polypeptide of claim 1.

3. A vector comprising the nucleic acid molecule of claim 2.

4. A cell comprising the vector of claim 3.

5. The use of the polypeptide of claim 1 in either (I) or (II): (I) Preparation of microbial inhibitors, wherein the microorganism is a bacterium, and the bacterium is at least one of Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus; (II) Preparation of cosmetic additives.

6. A method of producing the polypeptide of claim 1, comprising, The polypeptide was prepared by Fmoc solid-phase synthesis.

7. A drug comprising the polypeptide of claim 1.

8. The medicament according to claim 7, characterized in that, The drug also contains antibiotics.

9. The medicament according to claim 8, characterized in that, The antibiotics include colistin.

10. A cosmetic additive comprising the polypeptide of claim 1.

11. A method for inhibiting microbial growth for non-disease treatment purposes, comprising the step of applying a drug according to any one of claims 7-9 or a cosmetic additive according to claim 10, wherein the microorganism is a bacterium, and the bacterium is at least one selected from Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus.